NOTE: This article was originally published in March 2026 as part of our PharPoint of View LinkedIn newsletter. Each month, our PharPOV series shares perspectives from across the PharPoint team: operational insights, trending topics, and stories about the behind-the-scenes collaboration that keeps studies moving. This article shares the perspective of Moya Hawkins, PharPoint’s Executive Director of Client Experience.

When Customer Service Isn’t Enough

Recently, the PharPoint team in Durham moved offices.

Our new space (just an elevator ride away into a third-floor suite within the same building) came fully furnished, leaving us with a significant amount of furniture and equipment that needed to be removed. A handful of vendors were lined up to assist with removal, donation, or return.

As our move-out day approached, vendor complications surfaced.

Previously agreed upon commitments were questioned at the last minute. Collection dates were missed without notice, then missed again following vague explanations and revised timelines. Teams arrived unprepared for the volume of furniture, despite earlier conversations to set expectations. As items were moved, walls were damaged and debris was left behind.

When concerns were raised, responses like “that’s above my pay grade,” or “I’m just doing my job” followed.

In our industry – this time from a sponsor’s point of view – clinical trial vendors can come with similar challenges and setbacks.

  • Timelines are missed without prior communication, requiring the sponsor to chase for updates;
  • Agreed scope is changed without prior discussion;
  • Deliverables contain avoidable, costly quality issues, followed by the explanation that instructions were executed as communicated; and
  • No clear escalation path exists when commitments are at risk.

Unfortunately, versions of these failures occur in our industry every day, even among large, well-known organizations that command a premium for their brand.

This is why “customer service” alone is not enough.

Service businesses must demonstrate visible ownership from initial contact through final delivery, especially in challenging moments. Teams must anticipate needs, communicate proactively, and take clear ownership of commitments. In challenging situations, we must respond with transparency, solutions, decisive action, and accountability.

While some CROs earn a seat at the table through brand familiarity, sponsors choose PharPoint for how we show up. We reinforce these values in every engagement, and they remain a defining PharPoint differentiator and a standard we actively uphold.

This month, as our Durham team settled into the new office space, we shared this same story internally as a reminder: service without ownership erodes trust, while service with accountability builds it.


About the Author

Moya Hawkins, Executive Director of Client Experience

Moya Hawkins is a seasoned clinical research executive with over 30 years of experience, specializing in biometrics, client partnership strategy, and transforming complex challenges into strategic success for sponsors. Her career began in clinical data management and progressed through leadership roles at several top-tier contract research organizations, where she built a reputation for operational excellence before joining PharPoint in 2011.

In her current role, Moya serves as the executive-level client navigator where she champions sponsor success by delivering proactive guidance, tailored solutions, and high-touch engagement across every phase of the clinical development lifecycle.


RELATED RESOURCES

When Customer Service Isn’t Enough | PharPOV Series

PharPoint's Exec. Director of Client Experience explains where customer service can fall short, based on conversations after a recent move.

Research is Personal | Video

Clinical trials are both scientific and deeply personal. This short video reflects the perspective that guides our work in supporting sponsors and patients.

Exploring Multiple Perspectives in Rare Disease Trials

What makes rare disease trials unique? Explore perspectives across functions from a rare disease CRO team.

CRO Study Team Continuity and Transparency

Will you actually be working with the team a CRO introduces you to in early discussions?

No Surprises: PharPoint’s Transparent Approach to Changes in Scope

How does your CRO handle changes in scope (CIS)? Learn more about PharPoint's transparent process.

Building Stronger Relationships between CROs and Small Biopharma: Ensuring Your Voice is Heard

Explore how effective communication and collaboration builds successful partnerships.
Written by: Theresa Hegar